May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Safety and Efficacy of Intravitreal Bevacizumab for Neovascular Age Related Macular Degeneration. Pilot Study
Author Affiliations & Notes
  • M.L. Abraham–Marin
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • M. Hernandez–Rojas
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • G. Alvarez
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • C.F. Cortes–Luna
    Retina, Clinica de Ojos, Bogota, Colombia
  • V. Morales–Canton
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • M. Martinez
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • O. Ustariz
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • A. Solis–Vivanco
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • E. Reyna–Castelan
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • H. Quiroz–Mercado
    Retina, Asociacion para Evitar la Ceguera en Mexico, Mexico, Mexico
  • Footnotes
    Commercial Relationships  M.L. Abraham–Marin, None; M. Hernandez–Rojas, None; G. Alvarez, None; C.F. Cortes–Luna, None; V. Morales–Canton, None; M. Martinez, None; O. Ustariz, None; A. Solis–Vivanco, None; E. Reyna–Castelan, None; H. Quiroz–Mercado, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5239. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.L. Abraham–Marin, M. Hernandez–Rojas, G. Alvarez, C.F. Cortes–Luna, V. Morales–Canton, M. Martinez, O. Ustariz, A. Solis–Vivanco, E. Reyna–Castelan, H. Quiroz–Mercado; Safety and Efficacy of Intravitreal Bevacizumab for Neovascular Age Related Macular Degeneration. Pilot Study . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5239.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the Safety and efficacy of intravitreal bevacizumab for neovascular age related macular degeneration (ARMD)

Methods: : Patients with diagnosis of choroidal neovascularization associated with ARMD were injected with 1.25 mg of bevacizumab. Ophthalmologic evaluations included Best Corrected Visual acuity (BCVA) measurements, biomicroscopic and fundus examination, along with optical coherence tomography (OCT) imaging, fluorescein angiography and multifocal electroretinogram. Safety assessments were performed, along with assessments of changes from baseline in BCVA , OCT measurements, electroretinographic records, and angiographic lesion characteristics at one, three and six months postinjection.

Results: : 50 patients were injected, until now 25 patients completed the one month follow–up, whose results are presented here. The mean age was 72+/– 5.3 year–old. There were no serious ocular or systemic adverse events identified. Mean BCVA was 20/216 and mean foveal thickness was 417+/– 72 micron. One month mean BCVA was 20/257 and foveal thickness was 335 +/– 78 micra. There was not statistically significant differences between BCVA and foveal thickness (p=0.57 and p=0.068 Wilcoxon signed rank test)

Conclusions: : Intravitreal bevacizumab is safe, baseline BCVA and foveal thickness were better one month post injection but not statistically significant differences was demonstrated. Long term follow–up should be completed.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×